Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
NEW YORK, June 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, "Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market. The report identifies the key trends shaping and driving the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Introduction 8
2.1 Overview 8
2.1.1 Hospital-acquired MRSA (HA-MRSA) 8
2.1.2 Community-acquired MRSA (CA-MRSA) 8
2.1.3 Historical Aspect of MRSA Infection 9
2.1.4 Genetic Variance between CA-MRSA and HA-MRSA 9
2.2 Epidemiology 11
2.2.1 Historic Epidemiology (2006-2011) 11
2.2.2 Forecasted Epidemiology (2011-2019) 11
2.3 Prognosis 13
2.4 Etiology 13
2.5 Symptoms 14
2.6 Diagnosis 15
2.6.1 Bacterial Culture 15
2.6.2 ChromAgar Technique 15
2.6.3 Latex Agglutination Test 15
2.6.4 Molecular Detection 15
2.7 Pathophysiology 16
2.7.1 Molecular Pathogenesis of MRSA 16
2.7.2 Mechanism of Resistance 18
2.7.3 Transmission of MRSA 18
2.8 Treatment and Management Pattern 19
2.9 Referral Pathway 22
2.10 GlobalData Pipeline Report Guidance 23
3 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Market Characterization 24
3.1 MRSA Therapeutics Market Size (2006-2011) - Global 24
3.2 MRSA Therapeutics Market Forecast (2011-2019) - Global 26
3.3 MRSA Therapeutics Market Size (2006-2011) - The US 28
3.4 MRSA Therapeutics Market Forecast (2011-2019) - The US 29
3.5 MRSA Therapeutics Market Size (2006-2011) - France 30
3.6 MRSA Therapeutics Market Forecast (2011-2019) - France 31
3.7 MRSA Therapeutics Market Size (2006-2011) - Germany 32
3.8 MRSA Therapeutics Market Forecast (2011-2019) - Germany 33
3.9 MRSA Therapeutics Market Size (2006-2011) - Italy 35
3.10 MRSA Therapeutics Market Forecast (2011-2019) - Italy 36
3.11 MRSA Therapeutics Market Size (2006-2011) - Spain 38
3.12 MRSA Therapeutics Market Forecast (2011-2019) - Spain 39
3.13 MRSA Therapeutics Market Size (2006-2011) - The UK 41
3.14 MRSA Therapeutics Market Forecast (2011-2019) - The UK 42
3.15 MRSA Therapeutics Market Size (2006-2011) - Japan 44
3.16 MRSA Therapeutics Market Forecast (2011-2019) - Japan 45
3.17 Drivers and Barriers for the MRSA Therapeutics Market 46
3.17.1 Drivers for the MRSA Therapeutics Market 46
3.17.2 Barriers for the MRSA Therapeutics Market 46
3.18 Opportunity and Unmet Need 48
3.19 Key Takeaway 51
4 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - - Competitive Assessment 52
4.1 Overview 52
4.2 Strategic Competitor Assessment 52
4.3 Product Profile for the Major Marketed Products in the MRSA Therapeutics Market 54
4.3.1 Zyvox (linezolid) 54
4.3.2 Cubicin (daptomycin) 55
4.3.3 Tygacil (tigecycline) 57
4.3.4 Vibativ (telavancin) 58
4.3.5 Teflaro (ceftaroline) 59
4.3.6 Vancocin (vancomycin) 61
4.4 Key Takeaway 63
5 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment 64
5.1 Overview 64
5.2 Strategic Pipeline Assessment 64
5.3 MRSA Therapeutics- Pipeline Analysis by Phase of Development 65
5.3.1 MRSA Therapeutics- Phase III Pipeline 65
5.3.2 MRSA Therapeutics- Phase II Pipeline 66
5.3.3 MRSA Therapeutics- Phase I Pipeline 67
5.3.4 MRSA Therapeutics- Pre-Clinical Pipeline 68
5.3.5 MRSA Therapeutics- Discovery Pipeline 69
5.3.6 MRSA Therapeutics- Unknown Phase Pipeline 70
5.4 MRSA Therapeutics- Pipeline by Mechanism of Action 71
5.5 Technology Trends Analytical Framework 73
5.6 Most Promising Drug Profiles 74
5.6.1 Torezolid phosphate (TR-701, Tedizolid) 74
5.6.2 Ceftobiprole Medocaril 75
5.6.3 Dalbavancin 76
5.6.4 Oritavancin 77
5.7 Key Takeaway 77
6 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics -Clinical Trials Mapping 78
6.1 Clinical Trials by Region and Country 78
6.2 Clinical Trials by Phase of Clinical Development 79
6.3 Clinical Trials by Trial Status 80
6.4 Clinical Trials by Sponsors 81
6.5 Top Companies Participating in MRSA Clinical Trials 83
7 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Strategic Assessment 84
7.1 Key Events Impacting the Future Market 84
7.2 Future Market Competition Scenario 85
8 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Future Players 87
8.1 Introduction 87
8.2 Company Profiles 88
8.2.1 Basilea Pharmaceutica Ltd. 88
8.2.2 Durata Therapeutics, Inc. 89
8.2.3 The Medicines Company 89
8.2.4 Trius Therapeutics, Inc. 90
8.2.5 AstraZeneca PLC 91
8.2.6 GlaxoSmithKline plc 93
8.2.7 Rib-X Pharmaceuticals, Inc. 94
8.2.8 Wockhardt Limited 95
8.3 Details of Other Companies in the Pipeline 97
8.4 Key Takeaway 100
9 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Licensing and Partnership Deals 101
10 KOL Insights 104
11 Methicillin - resistant Staphylococcus aureus (MRSA) Therapeutics - Appendix 105
11.1 Definitions 105
11.2 Abbreviations 105
11.3 Bibliography 107
11.4 Research Methodology 108
11.4.1 Coverage 108
11.4.2 Secondary Research 108
11.4.3 Forecasting 109
11.4.4 Primary Research 111
11.4.5 Expert Panel Validation 112
11.5 Contact Us 112
11.6 Disclaimer 112
List of Tables
Table 1: Historic Epidemiology, Prevalent Population, 2006-2011 11
Table 2: Forecasted Epidemiology, Prevalent Population, 2011-2019 11
Table 3: Recommendations for the Treatment of Methicillin-Resistant Staphylococcus aureus 21
Table 4: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Global, Revenue ($m), 2006-2011 25
Table 5: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Global, Forecast ($m), 2011-2019 27
Table 6: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The US, Revenue ($m), 2006-2011 28
Table 7: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The US, Forecast ($m), 2011-2019 29
Table 8: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, France, Revenue ($m), 2006-2011 30
Table 9: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, France, Forecast ($m), 2011-2019 31
Table 10: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Germany, Revenue ($m), 2006-2011 32
Table 11: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Germany, Forecast ($m), 2011-2019 34
Table 12: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Italy, Revenue ($m), 2006-2011 35
Table 13: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Italy, Forecast ($m), 2011-2019 37
Table 14: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Spain, Revenue ($m), 2006-2011 38
Table 15: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Spain, Forecast ($m), 2011-2019 40
Table 16: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The UK, Revenue ($m), 2006-2011 41
Table 17: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The UK, Forecast ($m), 2011-2019 43
Table 18: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Japan, Revenue ($m), 2006-2011 44
Table 19: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Japan, Forecast ($m), 2011-2019 45
Table 20: Methicillin - Resistant Staphylococcus aureus Therapeutics - Drug Information 62
Table 21: Methicillin - Resistant Staphylococcus aureus Therapeutics - Phase III Pipeline, 2012 65
Table 22: Methicillin - Resistant Staphylococcus aureus Therapeutics - Phase II Pipeline, 2012 66
Table 23: Methicillin - Resistant Staphylococcus aureus Therapeutics - Phase I Pipeline, 2012 67
Table 24: Methicillin - Resistant Staphylococcus aureus Therapeutics - Pre-Clinical Pipeline, 2012 68
Table 25: Methicillin - Resistant Staphylococcus aureus Therapeutics - Discovery Pipeline, 2012 69
Table 26: Methicillin - Resistant Staphylococcus aureus Therapeutics - Unknown Phase Pipeline, 2012 70
Table 27: Development Status of Ceftobiprole 76
Table 28: Development status of Dalbavancin 77
Table 29: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Clinical Trials, 2012 78
Table 30: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Clinical Trials by Phase, 2012 79
Table 31: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Clinical Trials by Status of Development, 2012 80
Table 32: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Overall Sponsors, 2012 81
Table 33: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Prominent Sponsors, 2012 82
Table 34: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Top Ten Companies by Phase, 2012 83
Table 35: Basilea - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 88
Table 36: Durata Therapeutics - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 89
Table 37: The Medicines Company - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 90
Table 38: Trius Therapeutics - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 91
Table 39: AstraZeneca - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 92
Table 40: GlaxoSmithKline Pipeline Products 2012 94
Table 41: Rib-X Pharmaceuticals - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 95
Table 42: Wockhardt - Methicillin - Resistant Staphylococcus aureus Therapeutics Pipeline, 2012 96
Table 43: Description of Other Companies in the Pipeline, 2012 97
Table 44: Methicillin - Resistant Staphylococcus aureus Therapeutics, Licensing and Partnership Deals, 2012 101
List of Figures
Figure 1: Classification of Methicillin-Resistant Staphylococcus aureus Infection 9
Figure 2: Methicillin-Resistant Staphylococcus aureus Therapeutics - Comparison of HA-MRSA and CA-MRSA Infections 10
Figure 3: Methicillin-Resistant Staphylococcus aureus Therapeutics - Treatment Flow Analysis 12
Figure 4: KOL Insights, Methicillin - Resistant Staphylococcus aureus in the US 12
Figure 5: Methicillin-Resistant Staphylococcus aureus Therapeutics - Skin Infection (abscess) 14
Figure 6: Methicillin-Resistant Staphylococcus aureus Therapeutics - Comparison of Method of Detection 16
Figure 7: Virulence factors of S. aureus 17
Figure 8: Clinical Spectrum of Methicillin - Resistant Staphylococcus aureus Cases 17
Figure 9: Susceptibility of Antibiotics for Methicillin - Resistant Staphylococcus aureus 18
Figure 10: Methicillin-Resistant Staphylococcus aureus Therapeutics - Treatment Algorithm 20
Figure 11: Methicillin-Resistant Staphylococcus aureus Therapeutics - Management of Infection 21
Figure 12: Methicillin - Resistant Staphylococcus aureus Therapeutics - Referral Pathway 22
Figure 13: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Global, Revenue ($m), 2006-2011 25
Figure 14: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Global, Forecast ($m), 2011-2019 27
Figure 15: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The US, Revenue ($m), 2006-2011 28
Figure 16: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The US, Forecast ($m), 2011-2019 29
Figure 17: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, France, Revenue ($m), 2006-2011 30
Figure 18: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, France, Forecast ($m), 2011-2019 31
Figure 19: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Germany , Revenue ($m), 2006-2011 32
Figure 20: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Germany, Forecast ($m), 2011-2019 33
Figure 21: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Italy, Revenue ($m), 2006-2011 35
Figure 22: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Italy, Forecast ($m), 2011-2019 36
Figure 23: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Spain, Revenue ($m), 2006-2011 38
Figure 24: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Spain, Forecast ($m), 2011-2019 39
Figure 25: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The UK, Revenue ($m), 2006-2011 41
Figure 26: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, The UK, Forecast ($m), 2011-2019 42
Figure 27: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Japan, Revenue ($m), 2006-2011 44
Figure 28: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Japan, Forecast ($m), 2011-2019 45
Figure 29: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, Drivers and Barriers, 2012 47
Figure 30: Comparison of First and Second Generation Oxazolidinone 48
Figure 31: Comparison of Advantages and Disadvantages of Torezolid With Vancomycin and Linezolid 49
Figure 32: Opportunity and Unmet Need in the Methicillin - Resistant Staphylococcus aureus Therapeutics Market, 2012 50
Figure 33: KOL Insights, Unmet Medical Needs 51
Figure 34: Strategic Competitor Assessment of the Marketed Products in Methicillin - Resistant Staphylococcus aureus Therapeutics, 2012 52
Figure 35: KOL Insights, Limitation of Available Treatment Options 53
Figure 36: Molecular Structure of Linezolid 54
Figure 37: Molecular Structure of Daptomycin 55
Figure 38: Molecular Structure of Tigecycline 57
Figure 39: Molecular Structure of Telavancin Hydrochloride 58
Figure 40: Molecular Structure of Ceftaroline 60
Figure 41: Molecular Structure of Vancomycin Hydrochloride 61
Figure 42: Methicillin - Resistant Staphylococcus aureus Therapeutics- Clinical Pipeline by Phase of Development (%), 2012 70
Figure 43: Methicillin - Resistant Staphylococcus aureus Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2012 71
Figure 44: Methicillin - Resistant Staphylococcus aureus Therapeutics, Clinical Pipeline by Drug Class (%), 2012 72
Figure 45: Technology Trends Analytics Framework, 2012 73
Figure 46: Technology Trends Analytics Framework - Description, 2012 74
Figure 47: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Clinical Trials by Country, 2012 78
Figure 48: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Clinical Trials by Phase (%), 2012 79
Figure 49: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Clinical Trials by Status of Development (%), 2012 80
Figure 50: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Overall Sponsors (%), 2012 81
Figure 51: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Prominent Sponsors (%), 2012 82
Figure 52: Methicillin - Resistant Staphylococcus aureus Therapeutics, Global, Top Companies by Phase, 2012 83
Figure 53: Methicillin - Resistant Staphylococcus aureus Therapeutics Market, An Impact Analysis, 2012 84
Figure 54: Implications for Future Market Competition in the Methicillin - Resistant Staphylococcus aureus Therapeutics Market, 2012 85
Figure 55: Methicillin - Resistant Staphylococcus aureus Therapeutics, Clinical Pipeline by Company, 2012 87
Figure 56: KOL Insights, Methicillin - Resistant Staphylococcus aureus Infection, Major Market 104
Figure 57: GlobalData Market Forecasting Model 111
Companies mentioned
Basilea Pharmaceutica Ltd.
Durata Therapeutics, Inc.
The Medicines Company
Trius Therapeutics, Inc.
AstraZeneca PLC
GlaxoSmithKline plc
Rib-X Pharmaceuticals, Inc.
Wockhardt Limited
To order this report:
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article